From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy

The Lancet Regional Health. Europe · Published 2026-06-23 · DOI 10.1016/j.lanepe.2026.101757

Free full text

Authors (9)

Massimo Filippi, Giordano Cecchetti, Alma Ghirelli, Edoardo G. Spinelli, Giulia Rugarli, Stefano Pisano, Ana Maria Samanes Gajate, Arturo Chiti, Federica Agosta

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Filippi, M., Cecchetti, G., Ghirelli, A., et al. (2026). From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy. The Lancet Regional Health. Europe. https://doi.org/10.1016/j.lanepe.2026.101757

Related articles

• Estimating the Potential Burden of Clinically Significant Hantavirus Cases in Argentina · The Lancet Regional Health. Europe · 2026 · Same journal
• GLP-1 receptor agonists in type 1 diabetes: expanding the therapeutic landscape beyond insulin · The Lancet Regional Health. Europe · 2026 · Same journal
• Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease · The Lancet Regional Health. Europe · 2026 · Same journal
• Ending the Chronic Liver Disease Public Health Threat: Systemic Challenges Through the Patient Lens · The Lancet Regional Health. Europe · 2026 · Same journal
• Preparing Europe for Recurrent Autochthonous Dengue Transmission: Public Health Implications and Preparedness Priorities · The Lancet Regional Health. Europe · 2026 · Same journal
• Nordic AI-Health: a unique opportunity for discovery and clinical impact · The Lancet Regional Health. Europe · 2026 · Same journal
• Safety of the Dengue Vaccine TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain · The Lancet Regional Health. Europe · 2026 · Same journal
• Assessing Europe's policy readiness to confront the MASLD/MASH public health threat · The Lancet Regional Health. Europe · 2026 · Same journal
• Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension · The Lancet Regional Health. Europe · 2026 · Same journal
• Efficacy and Toxicity Associated with Cancer Drug Approvals in Switzerland: International Implications · The Lancet Regional Health. Europe · 2026 · Same journal